Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01495390 · ClinicalTrials.gov registry record
A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 139
- Enrollment target
NCT01495390: Completed study, sponsored by Massachusetts General Hospital.
NCT01495390 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 139 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01495390 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 139 participants
- Enrollment target
Study Summary
The purpose of this study is to collect biofluid samples for the banking and usage in ALS research. Through comparison of these samples, the researchers hope to learn more about the underlying cause of ALS, as well as find unique biological markers, which could be used to develop new therapies.
Primary Outcome
The ALSFRS-R is a quickly administered (5 min) ordinal rating scale used to determine a subject's assessment of their capability and independence in 12 functional activities. There are 12 questions, graded by the subject 0-4 (4 is normal). Score of 0 (worst) to 48 (best). Reflects speech and swallowing, fine motor skills, large motor skills, and breathing.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2011-11 |
| Est. Completion | 2016-12-31 |
What the finished NCT01495390 record still lists
NCT01495390 is an observational study that tracks outcomes without assigning an intervention. The registered 139 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01495390 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01495390 about?
NCT01495390 is a clinical study titled "A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers". The purpose of this study is to collect biofluid samples for the banking and usage in ALS research. Through comparison of these samples, the researchers hope to learn more about the underlying cause of ALS, as well as find unique biological markers, which could be used to develop new therapies.
What is the current status of trial NCT01495390?
This trial is currently completed. The enrollment target is 139 participants. The study started on 2011-11. Estimated completion is 2016-12-31.
Who is sponsoring clinical trial NCT01495390?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05645380 · 139 participants · Phase 2
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
- NCT06239272 · 139 participants · Phase 1
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
- NCT06252220 · 139 participants · Phase 1
First in Human Study in Subjects With Obesity, But Otherwise Healthy
- NCT06537128 · 139 participants · NA
Internet-delivered Cognitive-Behavioral Therapy for Adolescents With Autism and Anxiety
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia